Many reports have shown that several chemopreventive agents and anti-cancer drugs, including PPARγ ligands, resveratrol, aspirin, HDAC inhibitors, and proteasome inhibitors could improve the anti-cancer efficacy of TRAIL-based therapies [13,14,15,16]. Here, PPARG is linked to cancer.